Catalyst
Slingshot members are tracking this event:
Lilly's(LLY) Mirikizumab in Crohn's disease Phase 2 data due at DDW meeting 18-21 May, 2019
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| LLY | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 21, 2019
Occurred Source:
https://investor.lilly.com/news-releases/news-release-details/lillys-mirikizumab-met-primary-endpoint-and-key-secondary
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Mirikizumab, Crohn's Disease, Phase 2 Clinical Trial Data
